Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4001 + Bavencio in HPV-16 Positive Recurrent or Metastatic Malignancies
2024-515119-23-00Phase 2Authorised
- Sponsor
- Transgene SA
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of tipapkinogene sovacivec and avelumab in oropharyngeal squamous cell carcinoma (OPSCC), Cervical Cancer (CC), Vulval carcinoma and 3 more (3 arms), sponsored by Transgene SA. Primary endpoints: Safety and tolerability (Phase Ib), Overall response rate by RECIST 1.1 (Phase II part 1) and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
tipapkinogene sovacivecavelumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)Cervical Cancer (CC)Vulval carcinomavaginal cancerpenile cancer
Beyond the preview
Go deeper on 2024-515119-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515119-23-00.